EUCTR2011-005887-20-DE进行中（未招募）不适用
A prospective, randomized, double-blind, placebo-controlled, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the combined treatment of upper facial lines (horizontal forehead lines, glabellar frown lines, and lateral periorbital lines) - n/a
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Outpatients (male or female) 18 years of age or older.
- •Calculated cut-off score below 0 in evaluation based on the Freiburg Life Quality Assessment - ‘Lebensqualität, Haut und Kosmetik’ Questionnaire [FLQA-k]).
- •HFL, GFL, and symmetrical LPL of moderate to severe intensity at maximum contraction as assessed by the investigator according to the Merz Aesthetics Scales.
- •Stable medical condition.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 144
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 6
排除标准
- •Main Period:
- •Previous treatment with Botulinum toxin of any serotype in the forehead, glabellar, and/or periorbital area within the last 6 months before injection.
- •Previous treatment with any facial cosmetic procedure (e.g. dermal filling,chemical peeling, photo rejuvenation) in the forehead, glabellar, and/or periorbitalarea within the last 8 months before injection.
- •Any previous insertion of permanent material in the forehead, glabellar, and/or periorbital area (regardless of the time between previous treatment and this study).
- •Planned treatment with Botulinum toxin of any serotype in the face during the study period.
- •Any other planned facial cosmetic procedure in the face during the study period.
- •Very severe lines (HFL, GFL, and/or LPL) at maximum contraction as assessed by the investigator according to the Merz Aesthetics Scales.
- •Inability to substantially lessen UFL (HFL, GFL, LPL) by physically spreading them apart.
- •Any surgery or scars in the forehead, glabellar, or periorbital area.
- •Marked facial asymmetry.
- •Eyelid ptosis.
- •Marked brow ptosis.
- •History of facial nerve palsy.
- •Any infection and/or inflammation at the planned injection points.
研究者
相似试验
尚未招募
2 期
To evaluate the effectiveness of DigeSEB Super PB on digestion and gastrointestinal symptoms in healthy adultsCTRI/2023/10/058902Advanced Enzyme Technologies Ltd
进行中（未招募）
1 期
Safety and efficacy study of the simultaneous treatment of upper facial lines (horizontal forehead lines, glabellar frown lines and crows feet) in subjects with moderate to severe upper facial lines.Moderate to severe upper facial lines(horizontal forehead lines, glabellar frown lines, and lateral canthal lines)MedDRA version: 20.0Level: LLTClassification code 10048042Term: WrinklesSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 21.1Level: LLTClassification code 10052609Term: Glabellar frown linesSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: LLTClassification code 10052611Term: Crow's feetSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 21.1Level: PTClassification code 10040954Term: Skin wrinklingSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: SOCClassification code 10040785Term: Skin and subcutaneous tissue disordersSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2019-004113-13-DEMerz Pharmaceuticals GmbH368
尚未招募
不适用
Beta-alanine supplementation in patients with COPD receiving non-linear periodized exercise (NLPE) training: randomized placebo-controlled trial.Chronic obstructive pulmonary disease (COPD)Exercise intoleranceMuscle dysfunction.NL-OMON23943Radboudumc Board of Directors154
进行中（未招募）
1 期
A prospective, randomized, double-blind, placebo-controlled, international, multicentre, parallel-group comparison trial evaluating the efficacy and safety of single i.v. bolus tenecteplase plus standard anticoagulation as compared with standard anticoagulation in normotensive patients with acute pulmonary embolism and with echocardiographic (or spiral CT) and laboratory evidence of right ventricular dysfunction. - PEITHOPatients suffered from acut pulmonary embolism.EUCTR2006-005328-18-HUAssistance Publique - Hôpitaux de Paris (AP-HP)1,000
尚未招募
不适用
A Controlled parallel-group clinical study to assess the effect of a Bacillus coagulans-based product on immunomodulation and stress levelsCTRI/2020/07/026453Abode Biotec India Private Limited